Clinical Trials
34 trialsDutaBCa-1
CHU de Quebec-Universite Laval
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
CHU de Quebec-Universite Laval
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Pellficure Pharmaceuticals, Inc
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Endeavor Health
PROMED
Turku University Hospital
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Masonic Cancer Center, University of Minnesota
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
University of Illinois at Chicago
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
KHLAD
Dana-Farber Cancer Institute
TAPS
University of Washington
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia
Kaunas University of Medicine
ARI103094-Follow-Up Study for REDUCE Study Subjects
GlaxoSmithKline
Economic Analyses of the REDUCE Trial
GlaxoSmithKline
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
GlaxoSmithKline
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
GlaxoSmithKline
AVIAS
Canadian Urology Research Consortium
REDUCE
GlaxoSmithKline
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
University of Colorado, Denver
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
KHAD
Dana-Farber Cancer Institute
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
Bay State Clinical Trials, Inc.
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
University of California, San Francisco
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
National Cancer Institute (NCI)
Dutasteride in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Roswell Park Cancer Institute
ARTS
GlaxoSmithKline
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
Sunnybrook Health Sciences Centre
5aR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)